[Cell] To exploit LAG-3’s proximity to T cell receptor (TCR) and maximize LAG-3-dependent T cell suppression, scientists developed an Fc-attenuated LAG-3/TCR inhibitory bispecific antibody to bypass the requirement of cognate peptide-MHC class II.

[Nature Immunology] Researchers conducted an unbiased genome-wide CRISPR screen of primary macrophages. Their study confirmed the function of known regulators in tumor associated macrophage responses and revealed new insights into the behavior of these cells.

[Genome Biology] Scientists performed in-depth bioinformatic analysis and functional experiments for EOMES, finding that the nasopharyngeal carcinoma-risk alleles of four functional SNPs upregulate EOMES expression by promoting the activity of regulatory elements in T cells.

[Nature Immunology] The authors demonstrated that PD-1 deficiency enhances the function of T_reg cells through expression of a compensatory network of coinhibitory receptors.

[Science Translational Medicine] Scientists reported that postmortem and explanted human hypertrophic cardiomyopathy (HCM) hearts exhibited chronic focal leukocyte infiltration and prominent activation of immune cells. Gene set enrichment analysis revealed that active immune responses were present in the mid- and late-stage HCM human hearts and in mouse hearts from several HCM mouse models.

[Science Translational Medicine] Researchers showed that mice with systemic, Kupffer cell–specific, or myeloid cell–specific Mas1 deficiency were vulnerable to liver ischemia-reperfusion injury.

[Cellular & Molecular Immunology] Targeting stem-like CD4⁺ T cells offers great therapeutic potential: disrupting their persistence could mitigate autoimmune pathology and transplant rejection, whereas enhancing their effector capacity could improve antitumor immunity.

[Signal Transduction and Targeted Therapy] The authors explore the therapeutic potential of targeting pattern recognition receptors in treating infectious, inflammatory, autoimmune, and malignant diseases, underscoring their importance in advancing immunological research and precision medicine.

[Earendil Labs (BioSpace)] Earendil Labs announced that it has completed cohort 1 dosing in a Phase I trial for a novel anti-TL1A antibody (HXN-1001). HXN-1001 is a half-life extended next-generation anti-TL1A antibody for the treatment of patients with inflammatory bowel diseases, including ulcerative colitis, Crohn's disease, and other immunological disorders.

[Altimmune, Inc. ] Altimmune, Inc. announced that it has enrolled the first patient in the RESTORE Phase II trial evaluating the efficacy and safety of pemvidutide in subjects with ALD.

[NPJ Precision Oncology] Researchers reported that methyltransferase 21A (METTL21A) is significantly upregulated in HCC tissues and associated with poor clinical prognosis.

Upstream Bio, Inc. announced that the first patient has been dosed in the company’s Phase II clinical trial evaluating verekitug in patients with COPD,...